Phospho-p73 (Thr86) Antibody - #AF8296

(1)   (3)  
Product: Phospho-p73 (Thr86) Antibody
Catalog: AF8296
Description: Rabbit polyclonal antibody to Phospho-p73 (Thr86)
Application: WB
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Dog
Mol.Wt.: 80kDa; 70kD(Calculated).
Uniprot: O15350
RRID: AB_2840358

View similar products>>

   Size Price Inventory
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%), Bovine(100%), Sheep(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Phospho-p73 (Thr86) Antibody detects endogenous levels of p73 only when phosphorylated at Thr86.
RRID:
AB_2840358
Cite Format: Affinity Biosciences Cat# AF8296, RRID:AB_2840358.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Delta N p73; DNp73; p53 like transcription factor; p53 related protein; P73; TP73;

Immunogens

Immunogen:

A synthesized peptide derived from human p73 around the phosphorylation site of Thr86.

Uniprot:

O15350(P73_HUMAN) >>Visit HPA database.

Gene(ID):
TP73(7161)
Expression:
O15350 P73_HUMAN:

Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue.

Sequence:
MAQSTATSPDGGTTFEHLWSSLEPDSTYFDLPQSSRGNNEVVGGTDSSMDVFHLEGMTTSVMAQFNLLSSTMDQMSSRAASASPYTPEHAASVPTHSPYAQPSSTFDTMSPAPVIPSNTDYPGPHHFEVTFQQSSTAKSATWTYSPLLKKLYCQIAKTCPIQIKVSTPPPPGTAIRAMPVYKKAEHVTDVVKRCPNHELGRDFNEGQSAPASHLIRVEGNNLSQYVDDPVTGRQSVVVPYEPPQVGTEFTTILYNFMCNSSCVGGMNRRPILIIITLEMRDGQVLGRRSFEGRICACPGRDRKADEDHYREQQALNESSAKNGAASKRAFKQSPPAVPALGAGVKKRRHGDEDTYYLQVRGRENFEILMKLKESLELMELVPQPLVDSYRQQQQLLQRPSHLQPPSYGPVLSPMNKVHGGMNKLPSVNQLVGQPPPHSSAATPNLGPVGPGMLNNHGHAVPANGEMSSSHSAQSMVSGSHCTPPPPYHADPSLVSFLTGLGCPNCIEYFTSQGLQSIYHLQNLTIEDLGALKIPEQYRMTIWRGLQDLKQGHDYSTAQQLLRSSNAATISIGGSGELQRQRVMEAVHFRVRHTITIPNRGGPGGGPDEWADFGFDLPDCKARKQPIKEEFTEAEIH

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
100
Sheep
100
Dog
100
Pig
88
Horse
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein.

PTMs:

Isoform alpha (but not isoform beta) is sumoylated on Lys-627, which potentiates proteasomal degradation but does not affect transcriptional activity. Phosphorylation by PLK1 and PLK3 inhibits the transcription regulator activity and pro-apoptotic function.

Higher levels of phosphorylation seen in the brain from patients with Huntington disease.

Polyubiquitinated by RCHY1/PIRH2; leading to its degradation by the proteasome.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Accumulates in the nucleus in response to DNA damage.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in striatal neurons of patients with Huntington disease (at protein level). Brain, kidney, placenta, colon, heart, liver, spleen, skeletal muscle, prostate, thymus and pancreas. Highly expressed in fetal tissue.

Family&Domains:

Possesses an acidic transactivation domain, a central DNA binding domain and a C-terminal oligomerization domain that binds to the ABL1 tyrosine kinase SH3 domain.

The PPxY motif mediates interaction with WWOX.

Belongs to the p53 family.

Research Fields

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Measles.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

References

1). CDK4/6 inhibition suppresses p73 phosphorylation and activates DR5 to potentiate chemotherapy and immune checkpoint blockade. CANCER RESEARCH, 2022 (PubMed: 35149588) [IF=12.5]

Application: WB    Species: Mice    Sample: tumors tissue

Figure 5. DR5 is required for the antitumor activity of combining Palbo and TRAIL or 5-FU in mice. (A)-(C) Nude mice with established WT or DR5-KO HCT116 xenografts were treated with TRAIL (i.p.; 100 μg/mice every other day), Palbo (oral gavage;150 mg/kg daily), or their combination as indicated. (A) Tumor volume at indicated time points with statistical significance for indicated comparisons (N=6 in each group). (B) Western blotting of DR5 and p-p73 (Thr86) in randomly selected WT tumors treated as in (A) for 4 consecutive days. (C) Tumor sections from mice treated as in (B) were analyzed for apoptosis by active caspase 3 staining (left panel) and quantification (right panel). Scale bars: 25 μm. (D)-(F) Nude mice with established WT or DR5-KO HCT116 xenografts were treated with 5-FU (i.p.; 25 mg/kg every other day), Palbo (oral gavage;150 mg/kg daily), or their combination as indicated. (D) Tumor volume at indicated time points with statistical significance for indicated comparisons (N=6 in each group). (E) Western blotting of DR5 in randomly selected WT tumors treated as in (D) for 4 consecutive days. (F) Tumor sections from mice treated as in (E) were analyzed for apoptosis by active caspase 3 staining (left panel) and quantification (right panel). Scale bars: 25 μm. In (C) and (F), arrows indicate examples of positive signals. Bar graphs show results of 300 cells in each mouse (N=3 in each group). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.